proprotein convertase subtilisin/kexin type 6Genealiases: PACE4 · SPC4
Q-omics provides the consensus-scored PCSK6 profile across patient tissues and cancer cell-line models. PCSK6 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, PCSK6 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, PCSK6 protein abundance shows 27,126 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRP, KIRC, and LSCC as cancer lineages where PCSK6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PCSK6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PCSK6 survival associations across molecular data types. PCSK6 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (6) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PCSK6 RNA expression–survival associations across cancer types. High PCSK6 expression shows unfavorable associations in KIRP, ACC and BLCA, but favorable associations in KIRC, BRCA and OV. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for PCSK6 RNA expression.
This table summarizes PCSK6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 9. The strongest signals are observed in KIRC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for PCSK6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PCSK6 shows lower tumor expression in KICH, THCA and COAD and higher tumor expression in KIRC, BRCA and BLCA. The KIRC box plot shows higher PCSK6 RNA expression in tumor versus normal tissue (log2 FC = +2.924, t-test p < 0.001).
This table shows molecular features associated with PCSK6 in patient tissues and cancer cell lines. In patient samples, PCSK6 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, PCSK6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and LARGE_INTESTINE.
